Welcome to our dedicated page for Elanco Animal Health SEC filings (Ticker: ELAN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Elanco Animal Health filings document the disclosures of a public animal health company focused on products for farm animals and pets. The record includes Form 8-K reports on operating results, clinical or regulatory matters, capital-structure updates, credit-facility amendments, investor presentations, and restructuring-related exit or disposal activities.
Elanco's proxy materials describe board composition, shareholder voting matters, executive compensation, equity awards, and governance practices. Its filings also provide formal disclosure around material events, financial reporting, and the capital arrangements that support the company's global animal health operations.
Elanco Animal Health director Paul Herendeen reported two equity awards in the form of common stock-based units. On May 21, 2026, he acquired 12,196 deferred stock units as a pro-rated annual equity award and 4,678 restricted stock units as an annual equity award for non-employee Board members. These are compensation-related grants at no cash cost to him, not open-market purchases or sales, and increase his equity-based stake in Elanco.
Elanco Animal Health director Deborah Turner Kochevar received an equity award of 4,678 shares of common stock on May 21, 2026. The Form 4 labels this as a grant or award acquisition at no cost per share, reported as a grant of deferred stock units for non-employee Board members. Following the award, she directly owns 94,392 shares of Elanco common stock. This is a routine director compensation grant rather than an open-market purchase.
HOOVER R DAVID reported acquisition or exercise transactions in this Form 4 filing.
Elanco Animal Health Inc director R. David Hoover received a grant of 4,678 shares of Common Stock as deferred stock units, described as a pro-rated annual equity award for non-employee board members. The award carried a grant price of $0.00 per share, reflecting its compensation nature rather than a market purchase.
After this grant, Hoover directly holds 111,451 shares of Elanco common stock. He also has indirect holdings reported through the Suzanne A. Hoover Revocable Trust with 15,920 shares and another Revocable Trust with 150,000 shares, providing additional indirect exposure to Elanco shares.
Harrington Michael J reported acquisition or exercise transactions in this Form 4 filing.
Elanco Animal Health director Michael J. Harrington reported equity awards of common stock on May 21, 2026. He received 12,196 deferred stock units as a pro-rated annual equity award and 4,678 restricted stock units as an annual equity award for non-employee board members, both at no cash cost.
Anand Kapila K reported acquisition or exercise transactions in this Form 4 filing.
Elanco Animal Health director Anand K. Kapila received equity compensation, not making any open-market trades. On May 21, 2026, he was granted 12,196 deferred stock units as a pro-rated annual equity award and 4,678 restricted stock units as an annual equity award for non-employee directors. Both awards were recorded at $0.00 per share, reflecting stock-based compensation rather than a purchase. After these grants, the filing reports his direct ownership of Elanco common stock at 99,651 shares.
Ma Stacey reported acquisition or exercise transactions in this Form 4 filing.
Elanco Animal Health Inc director Stacey Ma received equity awards in the form of company stock. On May 21, 2026, she was granted 12,196 shares of common stock as deferred stock units and 4,678 shares as restricted stock units, both described as annual equity awards for non-employee directors. These are compensation-related grants at no cash purchase price, not open-market stock purchases or sales.
Elanco Animal Health director Art A. Garcia reported receiving stock-based compensation in the form of common stock units. On May 21, 2026, he acquired 12,196 deferred stock units as a pro-rated annual equity award for non-employee directors and 4,678 restricted stock units as an annual equity award. Both awards were granted at a stated price of $0.00 per share, reflecting compensation rather than open-market purchases. Each line in the filing shows updated direct holdings of Elanco common stock of 108,152 shares and 95,956 shares, respectively, following these grants.
Elanco Animal Health officer Rajeev A. Modi bought 4,911 shares of common stock in an open-market purchase at $20.35 per share, bringing his direct holdings to 160,812 shares. He also received a grant of 74.3671 deferred stock units, each tied to one share or its cash equivalent, which settle after employment ends or in a specified future year.
Elanco Animal Health President and CEO Jeffrey N. Simmons reported an open-market purchase and a compensation-related award. A revocable trust associated with him bought 4,971 shares of common stock at $20.085 per share, bringing its indirect holdings to 171,971 shares. Separately, he received 142.3429 deferred stock units, each representing the right to one share of common stock or the cash equivalent, to be settled after employment ends or in a specified future year under the company’s Executive Deferral and Stock Match Plan. Following these updates, he directly holds 2,051,898 common shares and 24,306.4587 deferred stock units.
Elanco Animal Health EVP and CFO Robert M. VanHimbergen received a grant of 9.9204 deferred stock units tied to company common stock. The award is a compensation-related acquisition at a reference price of $19.86 per unit, bringing his total deferred stock units to 84.4197. Each unit represents the right to receive one share of common stock or the cash equivalent, settling in cash or shares after employment ends or in a specified future year under the company’s Executive Deferral and Stock Match Plan.